866-997-4948(US-Canada Toll Free)

Requip XL Analysis and Estimates from 2007 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 35 Pages


GlobalDatas pharmaceuticals report, Requip XL Analysis and Estimates from 2007 to 2020 provides Requip XL sales estimates for US and EU5 . In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Requip XL including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Requip XL including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2007-2020 for Requip XL in the US & EU5
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of content

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Parkinsons Disease 5
2.2 Symptoms of Parkinsons Disease 5
2.3 Diagnosis of Parkinsons disease 6
2.4 Parkinsons Disease Treatment Strategies 6
2.5 Parkinsons Disease Market 7
2.6 Epidemiology 7
2.7 Parkinsons Disease by Age and Gender 7
2.8 Etiology 8
2.9 GlobalData Report Guidance 8

3 Parkinsons Disease: Market Characterization 9
3.1 Parkinsons Disease Market 9
3.2 Parkinsons Disease Market Forecasts and CAGR 9
3.3 Factors Affecting Parkinsons Disease Market 10
3.3.1 High Prevalence: PD is the Second Most Frequent Neurodegenerative Disorder 10
3.3.2 Increase in Old Age Population 10
3.3.3 Patent Expiry of Prominent Drugs 10

4 Stages of Parkinsons Disease and Comparison of Treatments 11
4.1 The Hoehn and Yahr Scale 11
4.2 Modified Hoehn and Yahr Scale 11
4.3 The UPDRS 12

5 Staging of Parkinsons Disease 15
5.1 Distribution of Parkinsons disease Patients by Age Groups 15
5.2 Distribution of Patients by Stages 15

6 Requip XL 16
6.1 Introduction 16
6.2 Mechanism of Action 16
6.3 Clinical Studies 16
6.3.1 Study in Patients with Early Parkinson's Disease 16
6.3.2 Study in Patients with Advanced Parkinson's Disease 16
6.4 Approval History of Requip XL 17
6.5 Factors Affecting Sales of Requip XL 18
6.5.1 Used in Multiple Regimens 18
6.5.2 First Mover Advantage 18
6.5.3 Efficacy Profile 18
6.5.4 Dosing Convenience 18
6.5.5 Short Product Life Cycle 18
6.5.6 Generic Competition from Requip IR 18
6.5.7 Approval in Japan 18
6.6 Drug Evaluation 19
6.6.1 Drug Risk Benefit Score 19
6.6.2 Intensity of Competition 20
6.7 Sales Estimates 21
6.7.1 Target Patient Pool for Parkinsons Disease 21
6.7.2 Dosing 21
6.7.3 Market Penetration 21
6.7.4 Annual Cost of Therapy 22
6.7.5 Sales Estimates of Requip XL 23

7 Parkinson Disease Market: Appendix 31
7.1 Market Definitions 31
7.2 List of Abberiviations 31
7.3 Research Methodology 31
7.3.1 Coverage 31
7.3.2 Secondary Research 31
7.3.3 Forecasting 32
7.3.4 Number of Patients Approved to take the Drug 32
7.3.5 Net Penetration of Drug 32
7.3.6 Net Annual Dosing 33
7.3.7 Annual Cost of Therapy 33
7.3.8 Primary Research 33
7.3.9 Expert Panels 34
7.4 Drug Sales Estimates Model 34
7.5 Contact Us 34
7.6 Disclaimer 35
7.7 Sources 35

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 5
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 11
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 11
Table 4: Four Items, Part 1 of UPDRS 12
Table 5: Thirteen Items, Part 2 of Parkinsons disease 12
Table 6: Fourteen Items, Part 3 of UPDRS 13
Table 7: Fourteen Items, Part 3 of UPDRS 13
Table 8: Distribution of Parkinsons patients according to Hoehn and Yahr Classification 15
Table 9: Primary Efficacy Endpoint Results for Requip XL in Advanced Parkinsons Disease 17
Table 10: Approval History of Requip XL 17
Table 11: Drug Risk Benefit Score of Requip XL 19
Table 12: Efficacy Comparison of Requip XL with other Dopamine Agonists 20
Table 13: Efficacy Comparison of Requip XL with other Competitors 20
Table 14: Annual Cost of Requip XL for Parkinsons Disease, 2011 22
Table 15: Requip XL, Parkinsons Disease, Global, Sales Estimates ($m), 20072020 23
Table 16: Requip XL, Parkinsons Disease, The US, Sales Estimates ($m), 20082020 24
Table 17: Requip XL, Parkinsons Disease, The UK, Sales Estimates ($m), 20072020 25
Table 18: Requip XL, Parkinsons Disease, France, Sales Estimates ($m), 20072020 26
Table 19: Requip XL, Parkinsons Disease, Germany, Sales Estimates ($m), 20072020 27
Table 20: Requip XL, Parkinsons Disease, Italy, Sales Estimates ($m), 20072020 28
Table 21: Requip XL, Parkinsons Disease, Spain, Sales Estimates ($m), 20072020 29

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinson’s disease and Their Potential Sites of Action in the CNS
Figure 2: The Age-Specific Prevalence Rates of Parkinson’s Disease in the Elderly Among Five European Countries, 2003
Figure 3: Parkinson’s Disease, Global, Market Size Estimates ($bn), 2010-2020
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050
Figure 5: Points Distribution of UPDRS
Figure 6: Distribution of Parkinson’s patients by Hoehn & Yahr Classification
Figure 7: Drug Model Diagram of Requip XL in the US and EU
Figure 8: Requip XL, Parkinson’s Disease, Global, Sales Estimates ($m), 2007-2020
Figure 9: Requip XL, Parkinson’s Disease, The US, Sales Estimates ($m), 2008-2020
Figure 10: Requip XL, Parkinson’s Disease, The UK, Sales Estimates ($m), 2007-2020
Figure 11: Requip XL, Parkinson’s Disease, France, Sales Estimates ($m), 2007-2020
Figure 12: Requip XL, Parkinson’s Disease, Germany, Sales Estimates ($m), 2007-2020
Figure 13: Requip XL, Parkinson’s Disease, Italy, Sales Estimates ($m), 2007-2020
Figure 14: Requip XL, Parkinson’s Disease, Spain, Sales Estimates ($m), 2007-2020
Figure 15: Requip XL, Parkinson’s Disease, Global, Sales Distribution by Country (%), 2010
Figure 16: Drug Model Diagram
Figure 17: Patients Approved for the Drug

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *